JEFFERSON CITY, MO – October 27, 2026 – Missouri Attorney General Catherine Hanaway has issued a stern warning to pharmaceutical giant Eli Lilly, demanding the company immediately cease its practice of requiring hospitals to submit claims data as a prerequisite for receiving discounted medicines under the vital federal 340B Drug Pricing Program. This move signals a growing wave of state-level resistance against drugmakers’ unilateral changes to the program, which hospitals rely on to provide critical care to underserved communities.
n
In a forceful cease-and-desist letter dated October 26, Hanaway accused Eli Lilly of "breaking" its fundamental promise to provide eligible Missouri hospitals with statutorily mandated 340B discounts. She further contended that Lilly’s actions constitute "false and misleading statements," placing the company in direct violation of state law. The Attorney General’s office has set a firm deadline of November 26 for Eli Lilly to reverse its policy, or face further legal action.
n
The controversy centers on Eli Lilly’s recent requirement that hospitals provide granular claims data, a demand that many healthcare providers argue is an unnecessary administrative burden and a breach of the 340B program’s intent. Hanaway specifically highlighted the case of University of Missouri Health Care, which operates seven hospitals across the state. Despite the health system reportedly complying with Lilly’s data submission demands, the pharmaceutical company allegedly continued to deny the promised discounts on its essential medicines. This specific denial, Hanaway argues, underscores the deceptive nature of Lilly’s policy.
n
Main Facts
n
The core of Missouri’s challenge rests on the principle that Eli Lilly is imposing extra-statutory requirements that undermine the federal 340B program. The Attorney General’s letter asserts that drug manufacturers are legally obligated to offer 340B discounts to eligible covered entities without additional conditions beyond those explicitly outlined in federal statute.
n
Missouri Takes Stand Against Eli Lilly’s 340B Policy: Attorney General Catherine Hanaway’s cease-and-desist letter to Eli Lilly represents a direct legal challenge to the company’s restrictive 340B drug discount policies. The letter unequivocally states that Lilly has violated its agreement to sell medicines under the 340B program to eligible Missouri hospitals. Hanaway’s office interprets Lilly’s actions as a breach of contract and a form of deceptive trade practice, falling under the purview of Missouri’s consumer protection laws. The demand for an immediate halt to the policy by November 26 leaves little room for negotiation, indicating the state’s readiness to escalate the dispute.
n
The Heart of the Dispute: Claims Data Requirement: Eli Lilly, like several other pharmaceutical manufacturers, has unilaterally implemented a policy requiring 340B-eligible hospitals to provide extensive claims data for drugs dispensed through contract pharmacies. This data typically includes patient-level information, prescription details, and dispensing records. While manufacturers claim this data is necessary to prevent "duplicate discounts" and ensure program integrity, hospitals argue it creates an undue administrative burden, raises patient privacy concerns, and fundamentally alters the structure of the 340B program. They contend that existing federal oversight and audit mechanisms are sufficient to prevent abuse. Missouri’s stance is that this requirement is an unlawful precondition for accessing statutorily mandated discounts.
n
University of Missouri Health Care Case: A Tangible Grievance: The inclusion of University of Missouri Health Care’s experience provides concrete evidence for the Attorney General’s claims. According to Hanaway, despite the university health system reportedly agreeing to and providing the requested claims data, Eli Lilly still denied the crucial 340B discounts. This alleged denial, even after compliance, is central to Hanaway’s argument that Lilly’s demands are not genuinely about program integrity but rather a tactic to reduce its 340B obligations. It suggests that even hospitals willing to navigate the new bureaucratic hurdles are still being deprived of essential savings, thereby impacting their ability to serve vulnerable populations.
n
Chronology of Escalation
n
The current dispute between Missouri and Eli Lilly is not an isolated incident but rather the latest chapter in a multi-year saga surrounding the interpretation and enforcement of the 340B program.
n
The 340B Program: A Brief History and Its Purpose: The 340B Drug Pricing Program was enacted by Congress in 1992 as part of the Veterans Health Care Act. Its primary objective is to allow certain "covered entities" – primarily hospitals and clinics that serve a disproportionate share of low-income and uninsured patients – to purchase outpatient drugs at significantly discounted prices. The savings generated from these discounts are intended to enable these entities to "stretch scarce federal resources" to provide more comprehensive services, including expanding access to care, offering uncompensated care, and supporting community health initiatives for vulnerable populations. The program was a bipartisan effort to ensure that safety-net providers could continue their vital work despite financial constraints.
n
Drugmakers’ Shifting Stance and the Rise of Data Demands: For decades, the 340B program operated largely without direct manufacturer intervention in the claims process. However, in the late 2010s and early 2020s, a growing number of pharmaceutical companies began to express concerns about the program’s scope, particularly regarding contract pharmacies. Manufacturers argued that contract pharmacies, which dispense 340B drugs on behalf of covered entities, made it difficult to prevent "diversion" (drugs going to ineligible patients) or "duplicate discounts" (where both 340B and Medicaid rebates are applied to the same drug). Starting around 2020, companies like Eli Lilly, AstraZeneca, Sanofi, Novartis, and others unilaterally began imposing restrictions on 340B discounts for drugs dispensed through contract pharmacies, often demanding claims data as a condition for providing discounts.
n
Initial Regulatory Responses and Legal Challenges: The federal agency responsible for overseeing the 340B program, the Health Resources and Services Administration (HRSA), initially pushed back against these manufacturer restrictions. HRSA issued advisory opinions and enforcement letters, asserting that manufacturers were legally required to offer 340B discounts regardless of whether the drugs were dispensed through in-house or contract pharmacies. However, several pharmaceutical companies filed lawsuits challenging HRSA’s authority to enforce these requirements. Federal appeals courts delivered mixed rulings, with some siding with manufacturers, asserting that HRSA lacked the explicit statutory authority to mandate discounts for an unlimited number of contract pharmacies without specific regulatory guardrails. These court decisions created a vacuum, emboldening more manufacturers to impose their own data requirements and discount restrictions.
n
The Growing State-Level Backlash: In the wake of federal judicial setbacks for HRSA, states have increasingly stepped into the void, leveraging their own consumer protection and unfair trade practice laws to challenge drugmaker policies. Missouri’s action is part of a broader, concerted effort by state attorneys general and legislatures.
n
- n
- Arkansas was one of the first states to pass legislation explicitly prohibiting drug manufacturers from denying 340B discounts to contract pharmacies.
- Montana followed suit, enacting a law designed to protect 340B covered entities from manufacturer restrictions.
- Louisiana and Kansas have also seen legislative efforts aimed at safeguarding the 340B program within their borders.
- In California, Attorney General Rob Bonta has been particularly vocal, sending letters to multiple drugmakers warning against unlawful 340B restrictions and signaling potential legal action.
- States like Maryland, Mississippi, and North Dakota have also explored or enacted similar protective measures.nThis growing state-level pushback demonstrates a recognition that manufacturer actions are directly impacting the financial viability of local healthcare providers and the accessibility of care for state residents. These state-level challenges often pivot on arguments that manufacturers are engaging in deceptive practices, monopolistic behavior, or violating state consumer protection statutes by withholding statutorily mandated discounts.
n
n
n
n
n
n
Supporting Data and Context
n
Understanding the financial and operational impact of the 340B program is crucial to grasp the high stakes involved in this dispute.
n
The Financial Stakes: Billions in Discounts at Risk: The 340B program is substantial, accounting for billions of dollars in discounted drug purchases annually. Estimates vary, but some reports suggest the program generates over $30 billion in discounted drug sales each year. For eligible hospitals, these discounts can represent a significant portion of their pharmacy budgets, often ranging from 20% to 50% off the wholesale price of drugs. If manufacturers are successful in denying discounts, even partially, it could translate into hundreds of millions, if not billions, of dollars in lost savings for the healthcare safety net nationwide. This financial hit directly threatens the ability of hospitals to maintain essential services.
n
Impact on Patient Care and Hospital Services: 340B covered entities, especially rural hospitals, critical access hospitals, and disproportionate share hospitals, rely heavily on these savings to cross-subsidize a wide array of patient services. These include:
n
- n
- Uncompensated care: Providing care for uninsured and underinsured patients who cannot afford to pay.
- Specialty clinics: Funding for oncology, HIV/AIDS, diabetes, and mental health clinics.
- Community outreach programs: Health education, preventative screenings, and vaccination initiatives.
- Medication assistance programs: Helping low-income patients afford necessary prescriptions.
- Technology and infrastructure upgrades: Investing in electronic health records, new medical equipment, and facility improvements.
- Rural healthcare access: Many rural hospitals operate on thin margins, and 340B savings are often the difference between staying open or closing, thereby preserving access to care in underserved areas.
The denial of 340B discounts, therefore, is not merely a financial inconvenience; it directly jeopardizes patient access to vital services and can exacerbate health disparities.
n
n
Industry Arguments: Manufacturers’ Perspective: Pharmaceutical manufacturers, including Eli Lilly, have consistently articulated their rationale for imposing data requirements and restrictions. Their primary arguments include:
- Preventing Diversion: Manufacturers claim that without granular claims data, they cannot adequately track drugs dispensed through contract pharmacies, leading to a risk of 340B-discounted drugs being dispensed to ineligible patients.
- Eliminating Duplicate Discounts: They argue that data is essential to prevent instances where a drug receives both a 340B discount and a Medicaid rebate, which they contend is explicitly prohibited by statute.
- Ensuring Program Integrity: Manufacturers assert that their policies are aimed at maintaining the original intent and integrity of the 340B program, ensuring that discounts genuinely benefit the vulnerable patients they were designed for.
- Data for Patient Safety and Outcomes: Some manufacturers also suggest that collecting claims data can contribute to better understanding patient outcomes and drug utilization patterns, though this argument is often secondary to the financial and compliance concerns.
Hospital Arguments: Administrative Burden and Legal Precedent: Hospitals and 340B advocacy groups strongly refute the manufacturers’ claims, countering with several key points:
- Excessive Administrative Burden: They argue that collecting and transmitting the requested claims data is an onerous, expensive, and complex process that diverts resources from patient care. Many covered entities lack the sophisticated IT infrastructure to manage such demands.
- Violation of Statutory Intent: Hospitals contend that the 340B statute does not grant manufacturers the authority to impose additional conditions or data requirements beyond those specified in the law. They argue that manufacturers are attempting to unilaterally rewrite the program’s rules.
- Existing Audit Mechanisms: Covered entities point out that HRSA already has robust audit processes in place to monitor compliance and prevent diversion or duplicate discounts. They believe these mechanisms are sufficient and that manufacturers’ demands are redundant and unnecessary.
- No Explicit Statutory Language: The 340B statute does not mention contract pharmacy data submission requirements, and hospitals argue that manufacturers cannot invent new obligations.
- Patient Privacy Concerns: Hospitals also raise legitimate concerns about the security and privacy of sensitive patient data when it is shared with pharmaceutical manufacturers, citing potential HIPAA implications.
Official Responses and Legal Framework
The dispute in Missouri is unfolding within a complex legal and regulatory environment, with federal and state authorities, as well as the pharmaceutical industry, offering differing interpretations of the 340B program.
Missouri AG’s Legal Basis: Attorney General Hanaway’s cease-and-desist letter grounds its legal challenge in Missouri state law, specifically citing "false and misleading statements" and violations of state consumer protection statutes. By alleging that Eli Lilly has "broken" its promise to sell medicines under 340B, Hanaway frames the issue as a deceptive trade practice. State consumer protection laws typically prohibit businesses from engaging in unfair, deceptive, or fraudulent acts or practices in the conduct of commerce. The argument is that by participating in a federal program that mandates discounts, and then imposing arbitrary conditions that deny those discounts, Eli Lilly is acting deceptively and harming Missouri healthcare providers and, by extension, their patients. This approach allows states to intervene even when federal enforcement has been hampered by court rulings.
Eli Lilly’s Official Stance (Anticipated/General): While Eli Lilly has not yet issued a specific public response to Missouri’s cease-and-desist letter, the company’s general position on 340B contract pharmacy arrangements is well-documented. Lilly maintains that its data submission policy is a necessary measure to ensure compliance, prevent duplicate discounts, and safeguard the integrity of the 340B program. They argue that the intent of 340B was to benefit patients directly served by covered entities, not to create a revenue stream for large health systems through expansive contract pharmacy networks. Lilly, like other manufacturers, has also pointed to the aforementioned federal court rulings that have limited HRSA’s authority to mandate discounts for an unlimited number of contract pharmacies. Their anticipated response would likely reiterate these points, emphasizing their commitment to program integrity while suggesting that state actions overstep boundaries or misinterpret federal law.
Federal Government’s Role and Stance: HRSA, the federal agency tasked with administering 340B, has consistently maintained that manufacturers are obligated to provide 340B discounts for drugs dispensed through contract pharmacies. In late 2020 and early 2021, HRSA issued enforcement letters to several manufacturers, including Eli Lilly, stating that their actions were unlawful and demanding compliance. However, these enforcement efforts were subsequently challenged in federal courts. While HRSA has reaffirmed its position, the agency’s ability to compel compliance has been constrained by adverse court rulings that found HRSA exceeded its statutory authority in certain aspects of its enforcement. This legal landscape has created a vacuum, which states are now attempting to fill.
Legal Precedents and Ongoing Litigation: The legal battle over 340B contract pharmacy policies is far from over. Several federal appeals court decisions have created a complex and somewhat contradictory legal landscape. For example, the D.C. Circuit Court of Appeals ruled in favor of manufacturers in certain cases, stating that HRSA did not have the explicit statutory authority to require manufacturers to deliver 340B drugs to an unlimited number of contract pharmacies. However, these rulings did not explicitly endorse the manufacturers’ data demands or their right to deny discounts entirely. This has left room for states to pursue their own legal avenues, such as consumer protection laws, which operate independently of the federal 340B statute but can address the consequences of manufacturer actions within state borders. Numerous lawsuits are ongoing at both federal and state levels, indicating a protracted legal struggle.
Implications and Future Outlook
Missouri’s direct challenge to Eli Lilly carries significant implications for the future of the 340B program, drug pricing, and patient access across the nation.
Potential Escalation of State-Level Actions: If Attorney General Hanaway’s office succeeds in compelling Eli Lilly to reverse its policy, or if Missouri wins a subsequent lawsuit, it would set a powerful precedent. Such a victory would likely embolden other states that have been contemplating similar actions, leading to a cascade of challenges against pharmaceutical manufacturers. This could force drugmakers to reconsider their current strategies regarding 340B, potentially leading to more industry-wide concessions or a greater willingness to negotiate with covered entities. The collective pressure from multiple states could prove more effective than fragmented federal enforcement has been.
Impact on 340B Program Integrity and Future: The ongoing disputes threaten the stability and intended function of the 340B program. If manufacturers are allowed to impose arbitrary conditions or deny discounts, the program’s ability to support safety-net providers will be severely diminished. This could prompt Congress to revisit the 340B statute itself, potentially clarifying manufacturer obligations, HRSA’s enforcement authority, and the role of contract pharmacies. Legislative action, while historically difficult to achieve in healthcare, might become a necessity if the current legal and regulatory quagmire persists.
Financial Ramifications for Drugmakers and Hospitals: For Eli Lilly, a loss in Missouri could result in significant financial penalties, including potential restitution of denied discounts, fines, and legal fees. More importantly, it could necessitate a costly overhaul of its 340B compliance policies nationwide. For hospitals, particularly those in Missouri and other states considering similar action, a favorable outcome would mean the restoration of crucial 340B savings, allowing them to continue and expand vital patient services. Conversely, if manufacturers prevail, many safety-net hospitals could face severe financial strain, potentially leading to service reductions, layoffs, or even closures, especially in vulnerable rural areas.
Broader Implications for Drug Pricing and Access: This conflict is a microcosm of the larger, contentious debate over drug pricing, affordability, and access to medicines in the United States. Pharmaceutical companies face increasing pressure from policymakers and the public over high drug costs. Their actions to restrict 340B discounts are viewed by many as an attempt to claw back revenue, further exacerbating affordability issues. The outcome of these state-level battles will influence the balance of power between drug manufacturers and healthcare providers, potentially shaping future legislative and regulatory efforts to control drug spending and ensure equitable access to care. It could also encourage more transparency and accountability from all stakeholders in the drug supply chain.
The Path Forward: The immediate next step for Missouri is to await Eli Lilly’s response to the November 26 deadline. Should Lilly fail to comply, Attorney General Hanaway’s office is expected to initiate formal legal proceedings, likely through a lawsuit alleging violations of state consumer protection laws. This would trigger a potentially lengthy court battle, with discovery, motions, and potentially an injunction to compel Lilly to restore discounts. Meanwhile, 340B covered entities in Missouri and beyond will be closely watching, hoping that state action can succeed where federal efforts have faltered, thereby preserving a critical lifeline for healthcare access. The legal and political landscape surrounding 340B remains highly dynamic, with every new state challenge adding another layer to this intricate and high-stakes national debate.
